Selfdecode

Selfdecode

AI platform that provides personalized health recommendations based on DNA, labs and environment.

Print
Claim My Business
Security Type
Debt
Categories
Technology, Healthcare & Medical, Sports & Fitness
Min Investment
$100
Location
Los Angeles, CA
Offering Date
March 30, 2021
Expected Close Date
April 30, 2023
Target Raise
$50.00K-$4.46M
No. Investors
246
Security Price
$2.84
Valuation
$49,989,000
Website
selfdecode.com
Number of Employees
88
Cash
$5,803,097
Revenue
$2,645,709
Short Term Debt
$43,869
Cost of Goods
$427,791
Long Term Debt
$0
Net Income
$-2,400,488

Company Description

SelfDecode aims to provide an integrated AI platform that provides personalized health recommendations based on a combination of your DNA, labs, microbiome, and environmental factors.

SelfDecode was founded in 2016 and already offers users advanced reports which utilize artificial intelligence to provide targeted supplement, diet and lifestyle recommendations based on a person’s DNA. The platform also provides a lab analysis and tracker tool that gives personalized health recommendations designed to help users get their lab markers in the optimal range.

Key Deal Facts

Purpose: Provide consumers with a data-driven health software that provides better, more personalized recommendations.
Recurring Revenue: Predictable revenue stream from subscription sales model - $247 Lifetime Value of a Customer (LTV).
Large Margins & Scalable: High Avg Order Value of $179 - Low Cost of Goods Sold of ~$36 = $143 Gross Profit/Customer.
Proven Growth: 360% revenue growth from Q4 of 2019 to 2020 ($174,000 to $627,000). ~2M in total revenue in 2020.
Growth Potential: Digital health market will be worth $639B by 2026 & medical apps market size is growing at 23%/yr.
Highly Rated: 4.7 Trustpilot score, 98% retention rate, 64 NPS (Net Promoter Score) in Q4 and trending up.
Professional Experience: Team of 44 is composed of highly skilled scientists, MDs, PhDs, NDs and software engineers.
Operational Excellence: Bootstrapped to multimillion dollar revenue with only small seed investments (totaling $450K).

Management Team / Advisory Board Bios

Joseph Cohen, Founder, CEO
8+ years of professional executive experience in the health and biotech industry. Internationally recognized speaker and biohacker.
Growing up, I suffered from inflammation, brain fog, fatigue, digestive problems, anxiety, depression, & other issues that caused me to rack up medical bills. Finally, I started studying my genes and found solutions that actually worked to get rid of my health issues. I knew if personalized healthcare could work for me, it could work for others.

Puya Yazdi, Chief Scientific Officer
MD from USC, Resident Physician (Pathology) – Stanford University. Physician scientist with 15+ years of proven success in life sciences R&D, IP acquisition & science publications. Expertise in genomics, bioinformatics, biotech & nutraceuticals.
Amount Raised : $240,087
Reveal the Score by Voting
_
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.
Valuation

Security Description

Debt is something, usually money, borrowed by one party from another. Debt is used by many corporations and individuals to make large purchases that they could not afford under normal circumstances. A debt arrangement gives the borrowing party permission to borrow money under the condition that it is to be paid back at a later date, usually with interest.

Research Reports

No reports have been submitted

Become a Reporter

0 Comments